Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.67 |
| ▸ | IGF1R | P08069 | 8/20 | 0.64 |
| ▸ | ULK1 | O75385 | 1/20 | 0.61 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.61 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.61 |
| ▸ | AKT1 | P31749 | 1/20 | 0.61 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.61 |
| ▸ | GSK3A | P49840 | 1/20 | 0.61 |
| ▸ | GSK3B | P49841 | 1/20 | 0.61 |
| ▸ | STK4 | Q13043 | 1/20 | 0.61 |
| ▸ | STK3 | Q13188 | 1/20 | 0.61 |
| ▸ | BMPR2 | Q13873 | 1/20 | 0.61 |
| ▸ | STK26 | Q9P289 | 1/20 | 0.61 |
| ▸ | STK24 | Q9Y6E0 | 1/20 | 0.61 |
| ▸ | CCNK | O75909 | 1/20 | 0.60 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.60 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.60 |
| ▸ | SRC | P12931 | 2/20 | 0.59 |
| ▸ | PAK4 | O96013 | 2/20 | 0.55 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12060071 | 0.92 | NEK1 (0.67) | NEK1IGF1RAKT1TGFBR1GSK3A | |
| SCHEMBL12045464 | 0.83 | IGF1R (0.54) | NEK1IGF1RULK1PDK1ULK2 | |
| SCHEMBL16081590 | 0.81 | NEK1 (0.79) | NEK1IGF1RULK1AKT1TGFBR1 | |
| SCHEMBL1164159 | 0.80 | NEK1 (0.68) | NEK1IGF1RULK1AKT1TGFBR1 | |
| SCHEMBL15217634 | 0.80 | PAK1 (0.69) | NEK1IGF1RAKT1TGFBR1GSK3A | |
| SCHEMBL15217672 | 0.80 | PAK1 (0.61) | NEK1IGF1RPAK4PAK1 | |
| SCHEMBL15209036 | 0.79 | PAK1 (0.60) | NEK1IGF1RPAK4PAK1 | |
| SCHEMBL15217671 | 0.79 | PAK1 (0.60) | NEK1IGF1RCCNKCDK13CDK12 | |
| SCHEMBL15217688 | 0.79 | PAK1 (0.60) | NEK1IGF1RPAK4PAK1 | |
| SCHEMBL19654491 | 0.79 | ULK1 (0.71) | IGF1RULK1PDK1ULK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025151443-A1 | ENDOXIFEN FOR TREATMENT OF RARE CANCERS | ATOSSA THERAPEUTICS, INC. (US) | 2025-07-17 | — | — | WO | claimed |
| US-20240301429-A1 | COMPOSITIONS COMPRISING SASP MODULATORS AND SENESCENCE ATTENUATORS AND USES THEREOF FOR MODULATING CELLULAR SENESCENCE | RSEM, LIMITED PARTNERSHIP (CA) | 2024-09-12 | — | — | US | claimed |
| CN-117547511-A | Sugar response liposome, oriented electrospun membrane for bone regeneration in diabetes environment and preparation method thereof | 苏州大学附属第一医院 | 2024-02-13 | — | — | CN | claimed |
| CN-115969855-B | Application of APY29 in preparation of RSK4 kinase inhibitor | 中国人民解放军空军军医大学 | 2024-01-26 | — | — | CN | claimed |
| CN-116531382-B | Application of APY29 in preparation of medicine for treating esophageal squamous carcinoma | 中国人民解放军空军军医大学 | 2023-10-10 | — | — | CN | claimed |
| WO-2023163497-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING COLORECTAL CANCER COMPRISING EDNRA INHIBITOR AS ACTIVE INGREDIENT | 한국생명공학연구원 | 2023-08-31 | — | — | WO | claimed |
| CN-116531382-A | Application of APY29 in preparation of medicine for treating esophageal squamous carcinoma | 中国人民解放军空军军医大学 | 2023-08-04 | — | — | CN | claimed |
| US-20230190745-A1 | USE OF METABOLIC REGULATORS FOR THE TREATMENT OF COVID-19 | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2023-06-22 | — | — | US | claimed |
| CN-115969855-A | Application of APY29 in preparation of RSK4 kinase inhibitor | 中国人民解放军空军军医大学 | 2023-04-18 | — | — | CN | claimed |
| WO-2023023538-A2 | TREATING TISSUE INFLAMMATION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2023-02-23 | — | — | WO | claimed |
| CN-113262230-B | Targeted pig streptococcus serine and threonine protein kinase inhibitor and application thereof | 华中农业大学 | 2022-06-17 | — | — | CN | claimed |
| CN-113262230-A | Targeted pig streptococcus serine and threonine protein kinase inhibitor and application thereof | 华中农业大学 | 2021-08-17 | — | — | CN | claimed |
| US-20260140118-A1 | COMBINATION DRUG | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2026-05-21 | — | — | US | disclosed |
| EP-3368037-B1 | NOVEL METHODS OF TREATING HEARING LOSS | UNIV CALIFORNIA (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20250382291-A1 | SUBSTITUTED PYRROLO[2,3-b]PYRIDINES FOR SUPPRESSING TOXIC ENDOPLASMIC RETICULUM STRESS | UNIV COLUMBIA (US) | 2025-12-18 | — | — | US | disclosed |
| WO-2025151443-A1 | ENDOXIFEN FOR TREATMENT OF RARE CANCERS | ATOSSA THERAPEUTICS, INC. (US) | 2025-07-17 | — | — | WO | disclosed |
| EP-3656382-A1 | PERK AND IRE-1A INHIBITORS AGAINST NEURODEVELOPMENTAL DISORDERS | Université de Liège (BE) | 2020-05-27 | — | — | EP | disclosed |
| US-20190038597-A1 | PREVENTION OF VASCULAR AND CARDIAC FIBROSIS VIA IRE1ALPHA INHIBITION | MCMASTER UNIVERSITY (CA) | 2019-02-07 | — | — | US | disclosed |
| US-20190038597-A1 | PREVENTION OF VASCULAR AND CARDIAC FIBROSIS VIA IRE1ALPHA INHIBITION | MCMASTER UNIVERSITY (CA) | 2019-02-07 | — | — | US | disclosed |
| WO-2018138358-A1 | PERK AND IRE-1A INHIBITORS AGAINST NEURODEVELOPMENTAL DISORDERS | Université de Liège (BE) | 2018-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382291-A1 | SUBSTITUTED PYRROLO[2,3-b]PYRIDINES FOR SUPPRESSING TOXIC ENDOPLASMIC RETICULUM STRESS | HSPA5, ATP2A1, DNAJC10 | NEK1 2601/4885IGF1R 2902/4885ULK1 382/4885 |
| US-20260140118-A1 | COMBINATION DRUG | FGFR1, FGFR3, FGFR2 | NEK1 3248/4885IGF1R 53/4885ULK1 2160/4885 |
| US-20190038597-A1 | PREVENTION OF VASCULAR AND CARDIAC FIBROSIS VIA IRE1ALPHA INHIBITION | XBP1, ERN1, ERN2 | NEK1 2790/4885IGF1R 1313/4885ULK1 1383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.